Observational studyBMC cancer2020

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.

Mitsunori Morita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.